Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.

Ramy R SalehNicholas MetiDomen RibnikarHadar GoldvaserAlberto OcanaArnoud J TempletonBostjan SerugaEitan Amir

Published in: Cancer medicine (2020)

HRQoL is reported in only two-thirds of RCTs that describe collecting such data. Reporting of HRQoL is associated with positive trial outcome and higher journal impact factor, but not associated with overall safety and tolerability of anti-cancer drugs.

Keyphrases

phase iii
open label
placebo controlled
double blind
phase ii
clinical trial
study protocol
adverse drug
electronic health record
oxidative stress
emergency department
big data
randomized controlled trial
artificial intelligence